
    
      This study is a long-term extension study for evaluation of the safety and efficacy of
      TAK-385 following administration for 24 weeks (calculated from Visit 3 in the TAK-385/CCT-101
      study) in participants from the Phase II dose-finding study (TAK-385/CCT-101 study).
    
  